Toxic megacolon: A life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis

Bone Marrow Transplantation

Volumn 30, Issue 5, 2002, Pages 279-285

  Hayes Lattin, B M ^a   Curtin, P T ^a   Fleming, W H ^a   Leis, J F ^a   Stepan, D E ^a   Schubach, S ^a   Maziarz, R T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

AL amyloidosis; High dose chemotherapy; Stem cell transplantation; Toxic megacolon

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; OPIATE; STEROID; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ADULT; AMYLOIDOSIS; ANEMIA; ARTICLE; AUTOTRANSPLANTATION; CASE REPORT; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGLOBULIN DEPOSITION; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUTROPENIA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL; THROMBOCYTOPENIA; TOXIC MEGACOLON; TREATMENT OUTCOME; WHOLE BODY RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PATHOLOGY;

AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MEGACOLON, TOXIC; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036740627     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703627     Document Type: Article

References (34)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
2. Skinner M, Anderson J, Simms R et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290-298.
3. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New Engl J Med 1997; 336: 1202-1207.
4. Amoura Z, Leblond V, Azar N et al. High dose therapy and autologous stem cell transplantation (ASCT) for systemic amyloidosis (AQ: report of 9 cases (abstract). Arthritis Rheum 1998; 41: S234.
5. Moreau P, Leblond V, Bourquelot P et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766-769.
6. Lokhorst HM, Verdonck LF. Intensive therapy in AL amyloidosis and light-chain deposition disease (letter). Ann Intern Med 1995; 123: 553.
7. Comenzo RL, Falk RH, Sanchorawala V et al. Treating AL amyloidosis (AL) with dose-intensive melphalan: outcomes in 102 patients. Blood 1998; 92: 324a.
8. Gertz MA, Lacy MQ, Dispenzieri A. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000; 25: 465-470.
9. Dember LM, Sanchorawala V, Seldin DC et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on a1 amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746-753.
10. Gertz MA, Lacy MQ, Gastineau DA et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963-969.
11. Sanchorawala V, Wright DG, Seldin DC et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637-642.
12. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662-3670.
13. Reich G, Held T, Siegert W et al. Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2001; 27: 341-343.
14. Moreau P, Milpied N, de Faucal P et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996; 87: 3063-3064.
15. Patriarca F, Geromin A, Fanin R et al. Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura. Bone Marrow Transplant 1999; 24: 433-435.
16. Sezer O, Schmid P, Shweigert M et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999; 23: 967-969.
17. Anonymous. National Cancer Institute Common Toxicity Criteria. version 2.0. April 30, 1999.
18. Tzung SP, Hackman RC, Hockenbery DM et al. Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 1998; 4: 43-48.
19. Moreau P. Autologous stem cell transplantation for AL amyloidosis: a standard therapy? Leukemia 1999; 13: 1929-1931.
20. Majolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 1999; 84: 844-852.
21. Attal M, Horousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91-97.
22. Mehta J, Nagler A, Slavin S. Marrow transplantation in multiple myeloma. New Engl J Med 1992; 326: 1087; discussion 1087-1088.
23. Schulenburg A, Kalhs P, Oberhuber G et al. Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 1998; 22: 293-295.
24. Comenzo RL. Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned. Leuk Lymphoma 2000; 37: 245-258.
25. Sheth SG, LaMont JT. Toxic megacolon. Lancet 1998; 351: 509-513.
26. Carlson HC, Breen JF. Amyloidosis and plasma cell dyscrasias: gastrointestinal involvement. Semin Roentgenol 1986; 21: 128-138.
27. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220-224.
28. Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy. 3rd edn. Lippincott Williams and Wilkins: Philadelphia, 2001.
29. Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853-855.
30. Desikan KR, Dhodapkar MV, Hough A et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997; 27: 315-319.
31. Dispenzieri A, Lacy MQ, Kyle RA et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350-3356.
32. Majolino I, Marceno R, Pecoraro G et al. Autologous stem cell transplantation in amyloidosis AL. Bone Marrow Transplant 1993; 11: 85.
33. van Buren M, Hene RJ, Verdonck LF et al. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995; 122: 508-510.
34. Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 1997; 99: 245-256.